I'm a sophomore at Yale studying cognitive science and economics, drawn to the places where behavior and markets meet. I'm interested in how complex data becomes legible — and in building tools that close the gap between raw information and the decisions people actually make from it.
Currently spending the first part of the summer at Bluestar Global Management, a biotech-focused hedge fund, where I'm building research infrastructure and developing a view on emerging therapeutic areas. Originally from Hong Kong.
Building an earnings call language analyzer for biotech names — looking for patterns in management hedging, confidence shifts, and tone deltas across quarters. In parallel, researching the psychedelics therapeutic landscape — mapping the public and private companies developing compounds across clinical stages and indications. Building a public version of that landscape here.
13F Intelligence Tool
In production at a biotech hedge fundIngests 13F filings from biotech-focused hedge funds, parses positioning data, and surfaces consensus holdings, exit positions, and concentration changes — collapsing what was a multi-hour manual workflow into a single command. Built with Claude Code.
Earnings Call Language Analyzer
Live — try itAnalyzes earnings call transcripts for hedging language, confidence signals, and tone shifts quarter over quarter, synthesizing everything into charts that are easy to visualize and interpret. View code.
Biotech Research Agent
In development — summer 2026 / fall 2026An autonomous research agent that takes a ticker and assembles a structured research memo — chaining 13F positioning, earnings language analysis, clinical trial data, and FDA calendar events.
Psychedelics Therapeutics Landscape
OngoingA maintained map of the companies developing psychedelic-assisted therapies — public and private, organized by compound, clinical stage, and indication. An attempt to make a fast-moving, under-documented corner of biotech legible.